8-K filing — Apimeds Pharmaceuticals US, Inc. (APUS)
Filed: 2026-10-13 AccNo: 0001213900-26-108780 Size: 238 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Crypto · News reference
Apimeds Pharmaceuticals US' Subsidiary Mindwave Innovations Signs Three Agreements Between Sept. 24 And Oct. 4, 2026, To Build And Operate Dedicated Blockchain Networks For Clients In Climate Finance, Sports Media And Insurance
MindWave Innovations Inc. USA ("MindWave"), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS), signed three agreements between Sept. 24 and Oct. 4, 2026, to build and operate dedicated
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MindWave Innovations Signs 3 Client Network Agreements in 10 Days, Extending MindChain into Climate Finance, Sports Media and Insurance; Apimeds Pharmaceuticals US Provides Required NYSE American Disclosure
MindWave Innovations Inc. USA, a subsidiary of Apimeds Pharmaceuticals US, Inc., signed three blockchain network agreements within 10 days with AQUAE Holdings (climate finance), Flash Sports & Media Holdings (sports media), and BlockAssure Inc. (insurance). Each agreement follows the same model where MindWave builds and operates dedicated MindChain networks while receiving 20% token/credit allocations. However, the parent company disclosed substantial doubt about its ability to continue as a going concern.
Apimeds Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 30.94%